|
|
|
|
||
HC Stocks Zone: Titan Pharmaceuticals, Inc. (NASDAQ:TTNP)HC Stocks Zone: Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), Posted by: James Smith in Health Care May 30, 2016 Click For Article Shares of Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ended Friday session in red amid volatile trading. The shares closed down -0.21 points or -2.97% at $6.86 with 9.43 million shares getting traded. Post opening the session at $8.51, the shares hit an intraday low of $6.61 and an intraday high of $8.74 and the price vacillated in this range throughout the day. The company has a market cap of $133.69 million and the numbers of outstanding shares have been calculated to be 20.08 million shares. Titan Pharmaceuticals, Inc. (TTNP) on May 26, 2016 announced that the U.S. Food and Drug Administration has approved Probuphine® (buprenorphine) implant, the first product for the long-term maintenance treatment of opioid dependence in clinically stable patients on 8 mg or less a day of oral buprenorphine. The Probuphine subdermal implant, which utilizes Titan’s proprietary ProNeura™ technology, delivers buprenorphine continuously for up to six months. The product is expected to be commercially available this summer and is recommended for use as part of a complete treatment program including counseling and psychosocial support. “The approval of Probuphine marks a major milestone for Titan and we look forward to supporting our partner Braeburn Pharmaceuticals during the product launch this summer,” said Titan President and CEO Sunil Bhonsle. “At a time when the government is supporting the expansion of access to opioid addiction treatments, the launch of Probuphine will provide the medical community with a novel, long-term treatment alternative that can provide benefits to many patients suffering from this disease.” “As a clinician who has treated hundreds of patients for opioid addiction, including as a clinical investigator in the Probuphine studies, I am very encouraged by the prospects of this new treatment,” said Dr. Genie Bailey, Associate Clinical Professor of Psychiatry, Brown University and Director of Research, Stanley Street Treatment & Resources, Fall River, Massachusetts. “It’s extremely important that patients maintain their addiction treatment once they’ve stabilized on daily dosing of buprenorphine. Probuphine’s method of continuously delivering buprenorphine provides for long-term maintenance and offers the potential for enhanced patient compliance and a better quality of life.” Memorial Day Blessings to All TRUTH |
return to message board, top of board |